StockpollyBeta
Get App
Popularity #753
SMMT · NASDAQ · Biotechnology

Summit Therapeutics (SMMT)

Develops Akeso-origin ivonescimab through multinational late-stage oncology trials.

$16.98
vs last close−0.14 (−0.82%)

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
17283447445252414234225195220
Research & development13192436284140152131147133158
49911151212263103786363
General & administrative49911151212263103786363
Other expenses00000—000000
Operating income−17−28−34−47−44−52−52−414−234−225−195−220
−10−1−124322665
Interest income2200013033664
Interest expense333320000000
Other non-operating income0−3−2−12−4−4−30−2−6−6−5
Income before tax−17−29−34−48−42−49−49−412−232−219−189−216
Net income from continuing operations−17−29−34−48−42−49−49−412−232−219−189−216
Other adjustments000000000000
Net income−17−29−34−48−42−49−49−412−232−219−189−216
EPS, basic−$0.03−$0.04−$0.05−$0.07−$0.06−$0.07−$0.07−$0.56−$0.31−$0.29−$0.24−$0.28
EPS, diluted−$0.03−$0.04−$0.05−$0.07−$0.06−$0.07−$0.07−$0.56−$0.31−$0.29−$0.24−$0.28
Weighted average shares, basic698701702671703683699743743766775778
Weighted average shares, diluted698701702708727738738743743766775778
EBITDA−17−26−31−35−40−49−49−414−232−219−189−216
Depreciation & amortization000000000000
EBIT−17−26−31−35−40−49−49−414−232−219−189−216